+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
FEMALE
ID07234786

Single-Group Clinical Investigation Assessing Multi-Gyn FemiTotal Vaginal Gel for Treating and Preventing Symptoms of Bacterial Vaginosis and Vulvovaginal Candidiasis

Led by Karo Pharma AB · Updated on 2026-10-02

80

Participants Needed

1

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of Multi-Gyn FemiTotal vaginal gel for treating and preventing bacterial vaginosis BV and vulvovaginal candidiasis VVC symptoms in women. This trial includes 40 women with itching symptoms of VVC and 49 women with BV diagnosed using Amsel criteria. The main goal is to assess relief of itching and treatment effectiveness 21 days after starting the gel. Participants will use the Multi-Gyn FemiTotal vaginal gel for 7 days during the treatment phase. If symptoms are considered cured 21 days after starting treatment, they will enter a prevention phase where they are followed up for 4 months to monitor any recurrence of BV or VVC. The study is a single group, prospective clinical investigation led by Karo Pharma AB. During the study, participants will be evaluated by investigators using clinical assessments and questionnaires to measure treatment effectiveness at 21 days. Follow-up visits will continue until 4 months after treatment initiation to check for re-occurrence of infections. The study tracks symptom relief, treatment safety, and prevention of BV and VVC return over this period.

CONDITIONS

Brief Title

Multi-Gyn FemiTotal for the Treatment and Prevention of Vulvovaginal Candidiasis Symptoms and Bacterial Vaginosis

Research Team

D

Diana Zeneli, MD

J

Johan Ohlson

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here